0      0

M106 - Leveraging a Nucleic Acid Platform to Accelerate the Development of a SARS-CoV-2 Vaccine

‐ Jun 8, 2020 2:30pm

Given the COVID-19 global pandemic, there is a lot of work being done rapidly develop a SARS-CoV-2 vaccine. A human vaccine is essential for long term protection of high-risk individuals and health care workers. Traditional approaches to prophylactic vaccine development (e.g., attenuated strains of viruses or heat-inactivated viruses) have lengthy development timelines to establish safety and efficacy. This session will introduce the challenges with vaccine development in the face of a global pandemic and will provide some examples of where nucleic acid-based vaccines can be developed on rapid timelines. Technical talks will focus on two approaches that are being used today to develop vaccines for SARS-CoV-2 vaccines. In addition to speed to clinical testing, these approaches have the additional benefit of leveraging a platform nucleic acid technology that has potential to be scaled rapidly to allow for greater reach globally.


You must be logged in and own this session in order to post comments.